[HTML][HTML] Biodegradable nanoparticles mediated co-delivery of erlotinib (ELTN) and fedratinib (FDTN) toward the treatment of ELTN-resistant non-small cell lung cancer …

D Chen, F Zhang, J Wang, H He, S Duan… - Frontiers in …, 2018 - frontiersin.org
Background: Erlotinib (ELTN)-based targeted therapy as first-line treatment for epidermal
growth factor receptor (EGFR)-mutant lung cancers suffers from insufficient selectivity, side …

[引用][C] Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) Toward the Treatment of ELTN-Resistant Non-small Cell Lung …

D Chen, F Zhang, J Wang, H He, S Duan… - Frontiers in …, 2018 - cir.nii.ac.jp
Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN)
Toward the Treatment of ELTN-Resistant Non-small Cell Lung Cancer (NSCLC) via …

Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) Toward the Treatment of ELTN-Resistant Non-small Cell Lung Cancer …

D Chen, F Zhang, J Wang, H He… - Frontiers in …, 2018 - pubmed.ncbi.nlm.nih.gov
Background: Erlotinib (ELTN)-based targeted therapy as first-line treatment for epidermal
growth factor receptor (EGFR)-mutant lung cancers suffers from insufficient selectivity, side …

[HTML][HTML] Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) Toward the Treatment of ELTN-Resistant Non-small Cell Lung …

D Chen, F Zhang, J Wang, H He, S Duan… - Frontiers in …, 2018 - ncbi.nlm.nih.gov
Background: Erlotinib (ELTN)-based targeted therapy as first-line treatment for epidermal
growth factor receptor (EGFR)-mutant lung cancers suffers from insufficient selectivity, side …

Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) Toward the Treatment of ELTN-Resistant Non-small Cell Lung Cancer …

D Chen, F Zhang, J Wang, H He, S Duan… - Frontiers in …, 2018 - europepmc.org
Background: Erlotinib (ELTN)-based targeted therapy as first-line treatment for epidermal
growth factor receptor (EGFR)-mutant lung cancers suffers from insufficient selectivity, side …